Evidence map›Paper›PMID 29938344›Full record

ArticleEuropean journal of clinical pharmacology2018

Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.

Sourav Kalra, Raman Preet Kaur, Abhilash Ludhiadch, Gowhar Shafi, Rajesh Vashista, Raj Kumar, Anjana Munshi

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sourav KalraDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India.
Raman Preet KaurDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India.
Abhilash LudhiadchDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India.
Gowhar ShafiDepartment of Clinical Genomics and Bioinformatics, Positive Bioscience, Mumbai, India.
Rajesh VashistaMax super specialty Hospital, Bathinda, India.
Raj KumarLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, India. raj.khunger@gmail.com.
Anjana MunshiDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India. anjanadurani@yahoo.co.in.
Central University of Punjab · INMax Super Speciality Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCyclophosphamide and doxorubicin (adjuvant chemotherapy) are commonly used to treat breast cancer patients. Variation in the genes involved in pharmacodynamics and pharmacokinetics of these drugs plays an important role in prediction of drug response and survival. The present study was carried out with an aim to evaluate the variation in all the genes involved in pharmacokinetic and pharmacodynamics pathways of cyclophosphamide and doxorubicin, and correlate specific variants with disease outcome in breast cancer patients from the Malwa region of Punjab.

methodsA total of 250 confirmed breast cancer patients were involved in the study. Genotyping was performed on an Illumina Infinium HD assay platform using a Global Screening Array (GSA) microchip. GenomeStudio (Illumina, Inc.) was used for data preprocessing and a p value less than or equal to 5 × 10-8 was considered statistically significant. To rule out the influence of confounding risk factors, a step-wise multivariate regression analysis was carried out to evaluate the association of genotype with overall clinical outcome.

resultsTwo gene variants, CYP2C19 (G681A) and ALDH1A1*2 (17 bp deletion), were found to be significantly associated with the disease outcome, including overall survival, recurrence and metastasis, in breast cancer patients on adjuvant therapy. Both these genes are involved in the pharmacokinetics of cyclophosphamide. However, none of the variants in the genes involved in pharmacokinetics and pharmacodynamics of doxorubicin were found to have any significant impact on disease outcome in the studied group.

conclusionCYP2C19 (G681A) variant and ALDH1A1*2 emerged as two important biomarkers associated with bad outcome in breast cancer patients on adjuvant therapy.

Indexed as

AdultAgedAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyAntibiotics, AntineoplasticAntineoplastic Agents, AlkylatingBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideCytochrome P-450 CYP2C19DoxorubicinFemaleGenotypeHumansIndiaAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanAntibiotics, AntineoplasticAntineoplastic Agents, AlkylatingBiomarkers, TumorCyclophosphamideCYP2C19 protein, humanCytochrome P-450 CYP2C19DoxorubicinRetinal DehydrogenaseALDH1A1*1/*2CYP2C19*2Disease outcomeGene variantsGlobal screening arrayPharmacogenetics

Identifiers

PMID29938344
OpenAlexW2811102639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.